Hookipa Competitors

Stocks . USA . 
Stock . Hookipa Pharma
HOOK Stock  USD 1.00  0.01  1.01%   
Hookipa Pharma competes with Devonian Health, and Propanc Biopharma; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Hookipa Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Hookipa Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Hookipa Pharma Correlation with its peers.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

Hookipa Pharma vs Chimeric Therapeutics Correlation

Moving together with Hookipa Stock

  0.73FHTX Foghorn TherapeuticsPairCorr

Moving against Hookipa Stock

  0.78EVAX Evaxion Biotech ASPairCorr
  0.67MYGN Myriad GeneticsPairCorr
  0.52HUMA HumacytePairCorr
The value of Return On Tangible Assets is estimated to slide to -0.64. The value of Return On Capital Employed is expected to slide to -1.07. At this time, Hookipa Pharma's Total Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 836.3 K this year, although the value of Other Assets will most likely fall to 0.86.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.051.002.71
Details
Intrinsic
Valuation
LowRealHigh
0.061.202.91
Details
Naive
Forecast
LowNextHigh
0.020.992.69
Details
3 Analysts
Consensus
LowTargetHigh
1.822.002.22
Details

Hookipa Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Hookipa Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Hookipa and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Hookipa Pharma does not affect the price movement of the other competitor.

High positive correlations

PPCB
+ 0.79
NYMXF
NYMXF
+ 0.62
OXBOF
PPCB
+ 0.55
OXBOF
PPCB
+ 0.53
SRBCF
SRBCF
+ 0.43
NYMXF
LIANY
+ 0.36
LVCLF
  

High negative correlations

LIANY
- 0.71
NYMXF
PPCB
- 0.65
LVCLF
NYMXF
- 0.54
LVCLF
LIANY
- 0.53
OXBOF
PPCB
- 0.52
LIANY
OXBOF
- 0.47
LVCLF

Risk-Adjusted Indicators

There is a big difference between Hookipa Stock performing well and Hookipa Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Hookipa Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
LVCLF  1.84  0.55  0.00  0.59  0.00 
 0.00 
 0.00 
 0.00 
 61.22 
OXBOF  5.83  0.57  0.00  1.10  0.00 
 0.00 
 0.00 
(8.00)
 192.86 
IMUC  19.97  5.70  0.17  1.67  16.83 
(46.99)
 80.00 
(37.50)
 223.80 
NYMXF  9.84 (0.27) 0.00 (0.20) 0.00 
 0.00 
 36.54 
(23.42)
 68.44 
DVHGF  347.25  172.65  0.00  1.85  0.00 
 0.00 
 0.00 
 0.00 
 6,004 
HMTXF  2.72  0.19  0.01 (0.06) 3.94 
(6.53)
 9.87 
(8.76)
 41.09 
LIANY  4.82  0.92  0.07 (0.37) 5.71 
(10.79)
 12.12 
(11.43)
 60.61 
SRBCF  149.26  77.91  0.00 (0.71) 0.00 
 0.00 
 0.00 
 0.00 
 5,000 
PPCB  5.14 (2.48) 0.00  7.26  0.00 
 0.00 
 7.89 
(14.89)
 58.21 
CHMMF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 

Hookipa Pharma Competitive Analysis

The better you understand Hookipa Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Hookipa Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Hookipa Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HOOK LVCLF OXBOF IMUC NYMXF DVHGF HMTXF LIANY SRBCF PPCB
 1.01 
 1.00 
Hookipa
 0.00 
 0.01 
Living
 42.86 
 0 
Oxford
 47.37 
 0.10 
ImmunoCellular
 2.17 
 0.04 
Nymox
 5,906 
 4.27 
Devonian
 1.48 
 0.07 
Hemostemix
 2.15 
 0.1 
LianBio
 0.00 
 0.01 
Sirona
 17.86 
 0.23 
Propanc
Market Volatility
(90 Days Market Risk)
Risky
Out of control
Out of control
Out of control
Unknown risk
Out of control
Out of control
Out of control
Out of control
Out of control
Market Performance
(90 Days Performance)
Fair
Mild
Weak
Fair
Weakest
Good
Soft
Soft
Fair
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Low
Fair
High
Unknown
Small
Risky
Unknown
Low
Risky
Current Valuation
(Equity Enterprise Value)
Under Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Strong Sell
Cautious Hold
Strong Sell
Strong Buy
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
5.48
17.84
2.98
1.51
N/A
9.07
0.29
N/A
2.6
N/A
Net Asset
82.55 M
4.27 M
11.34 M
N/A
N/A
21.59 M
563.05 K
N/A
1.29 M
81.65 K
Profit Margin
N/A
N/A
N/A
N/A
N/A
-1.67
N/A
N/A
N/A
N/A
EBITDA
(40.85 M)
(2.38 M)
(6.16 M)
(6.07 M)
N/A
(1.65 M)
(6.53 M)
N/A
(2.3 M)
(2.14 M)
Operating Margin
-8.85
-428.7
-55.85
N/A
N/A
-1.48
N/A
N/A
-4.92
N/A
Current Valuation
(21.39 M)
12.53 M
37.52 M
(1.69 M)
N/A
42.9 M
9.27 M
N/A
24.5 M
1.53 M
Price To Book
0.43
6.96
0.19
0.35
N/A
2.75
39.23
N/A
36.93
N/A
Retained Earnings
(412.76 M)
(67 M)
N/A
(74.14 M)
N/A
N/A
(19.5 M)
N/A
(12.03 M)
N/A
Current Asset
26.61 M
6 M
N/A
24.56 M
N/A
N/A
175 K
N/A
1.49 M
N/A
Beta
0.9
0.27
1.21
1.03
N/A
1.22
0.54
N/A
-0.36
1.42
Number Of Employees
82
15
9
3
N/A
3
6
N/A
12
1
Shares Outstanding
9.93 M
1.29 B
146.71 M
4.19 M
N/A
134.69 M
75.74 M
N/A
251.73 M
1.76 B
Cash Flow From Operations
(76.98 M)
(2.04 M)
(5.18 M)
(2.31 M)
N/A
(2.87 M)
(3.48 M)
N/A
(2.16 M)
(1.44 M)
Total Debt
875 K
228.44 K
6.46 M
2.78 M
N/A
4.26 M
1.48 M
N/A
468.77 K
1.1 M
Return On Equity
-1.06
-0.72
-1.45
-23.12
N/A
-0.33
N/A
N/A
-35.56
N/A
Z Score
N/A
5.4
3.0
-2.8
N/A
4.8
-81.5
N/A
10.5
-85.8
Return On Asset
-0.45
-0.31
-0.4
-4.4
N/A
-0.12
-2.49
N/A
-1.35
-13.07
Number Of Shares Shorted
35.8 K
N/A
N/A
165.95 K
N/A
N/A
N/A
N/A
N/A
N/A
Book Value Per Share
2.71
0.003
0.026
-0.033
N/A
0.12
-0.052
N/A
0.004
-0.002
Current Liabilities
25.01 M
1000 K
N/A
2.27 M
N/A
N/A
1.49 M
N/A
801 K
N/A
Total Asset
82.55 M
4.27 M
11.34 M
30.08 M
N/A
21.59 M
563.05 K
N/A
1.29 M
81.65 K
Debt To Equity
0.052
0.1
0.99
0.39
N/A
0.31
N/A
N/A
0.6
N/A
Short Ratio
0.57
N/A
N/A
4.13
N/A
N/A
N/A
N/A
N/A
N/A
Target Price
2.0
N/A
N/A
5.0
N/A
N/A
N/A
N/A
N/A
1.52
Shares Owned By Institutions
12.16
N/A
52.68
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Market Capitalization
12.33 M
9.81 M
37.41 M
2.21 M
N/A
36.79 M
12.96 M
N/A
20.74 M
705.56 K
Price To Earning
12.06
-31.67
N/A
0.02
N/A
N/A
N/A
N/A
-7.33
-0.04
Price To Earnings To Growth
-0.19
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
1.32
5586.88
198.91
N/A
N/A
19.73
N/A
N/A
36.46
N/A
Net Income
(43.5 M)
(1.96 M)
(6.71 M)
(5.15 M)
N/A
(3.45 M)
(6.29 M)
N/A
(2.31 M)
(2.66 M)
Earnings Per Share
-4.82
-0.002
-0.088
28.91
N/A
N/A
-0.094
N/A
-0.012
-0.09
Shares Owned By Insiders
0.12
33.99
30.93
94.96
N/A
7.81
12.4
N/A
10.43
1.6
Revenue
43.95 M
3.4 K
154 K
N/A
N/A
2.31 M
N/A
N/A
268.02 K
N/A
Working Capital
56.01 M
5 M
N/A
22.29 M
N/A
N/A
(1.32 M)
N/A
692 K
N/A
Cash And Equivalents
117.92 M
4.24 M
4.59 M
933.15 K
N/A
9.49 M
649.32 K
N/A
1.13 M
4.07 K
Cash Per Share
2.16
N/A
0.05
0.01
N/A
0.07
0.01
N/A
N/A
N/A
Gross Profit
(50.47 M)
3.4 K
116 K
N/A
N/A
561.01 K
N/A
N/A
199.25 K
N/A
Day Typical Price
0.99
0.0079
0.002
0.12
0.044
4.27
0.0686
0.095
0.0051
0.22
Accumulation Distribution
79.74
N/A
N/A
37.0
318.82
N/A
N/A
N/A
N/A
29881.91
Market Facilitation Index
0.0
N/A
N/A
5.0E-4
0.0
N/A
N/A
N/A
N/A
N/A
Daily Balance Of Power
0.5
0.0
0
(1.80)
(0.20)
9.2 T
9.2 T
9.2 T
0.0
(2.50)
Period Momentum Indicator
0.01
N/A
(0)
(0.09)
(0)
4.1989
0.001
0.002
N/A
(0.05)
Rate Of Daily Change
1.01
1.0
0.57
0.53
0.98
60.06
1.01
1.02
1.0
0.82
Day Median Price
0.99
0.0079
0.002
0.13
0.0436
4.27
0.0686
0.095
0.0051
0.22
Price Action Indicator
0.015
N/A
(0.0008)
(0.07)
0.001
2.1
5.0E-4
0.001
N/A
(0.01)
Relative Strength Index
65.87
100.0
37.17
44.09
44.27
51.06
53.7
51.62
32.89
25.2
Coefficient Of Variation
864.63
1363.37
3700.83
639.05
(6,899)
580.05
4122.42
1038.09
829.23
(310.31)
Mean Deviation
1.28
1.84
5.83
19.97
9.84
347.25
2.72
4.82
149.26
5.14
Jensen Alpha
0.2224
0.5466
0.5711
5.7
(0.27)
172.65
0.1948
0.9177
77.91
(2.48)
Total Risk Alpha
0.1123
0.1917
(0.48)
4.02
(0.97)
126.65
(0.14)
0.4132
44.5
(2.86)
Sortino Ratio
0.0749
N/A
N/A
0.1655
N/A
N/A
0.0104
0.0659
N/A
N/A
Downside Variance
4.86
N/A
N/A
1224.02
N/A
N/A
66.62
148.92
N/A
N/A
Standard Deviation
1.82
8.06
22.2
37.29
15.36
1020.77
5.34
8.81
615.77
7.7
Kurtosis
1.82
52.07
33.5
9.68
2.75
30.36
6.58
7.45
65.95
5.47
Potential Upside
3.45
N/A
N/A
80.0
36.54
N/A
9.87
12.12
N/A
7.89
Treynor Ratio
(0.31)
0.591
1.1
1.67
(0.20)
1.85
(0.06)
(0.37)
(0.71)
7.26
Maximum Drawdown
7.38
61.22
192.86
223.8
68.44
6003.96
41.09
60.61
5000.0
58.21
Variance
3.3
64.91
492.83
1390.29
235.87
1041973.18
28.57
77.68
379167.3
59.35
Market Risk Adjusted Performance
(0.30)
0.601
1.11
1.68
(0.19)
1.86
(0.05)
(0.36)
(0.70)
7.27
Risk Adjusted Performance
0.0897
0.0621
0.0292
0.123
(0.001)
0.1347
0.0262
0.0788
0.0972
(0.22)
Skewness
0.3479
6.4
4.32
2.58
1.11
5.61
0.7406
1.29
8.12
0.4851
Semi Deviation
1.34
N/A
N/A
16.83
N/A
N/A
3.94
5.71
N/A
N/A
Information Ratio
0.0909
0.0678
0.025
0.1553
(0.02)
0.1724
0.0158
0.0912
0.1205
(0.33)
Value At Risk
(3.30)
N/A
(8.00)
(37.50)
(23.42)
N/A
(8.76)
(11.43)
N/A
(14.89)
Expected Short fall
(1.97)
N/A
N/A
(46.99)
N/A
N/A
(6.53)
(10.79)
N/A
N/A
Downside Deviation
2.2
N/A
N/A
34.99
N/A
N/A
8.16
12.2
N/A
N/A
Semi Variance
1.8
N/A
N/A
283.27
N/A
N/A
15.54
32.56
N/A
N/A

Hookipa Pharma Competition Performance Charts

Five steps to successful analysis of Hookipa Pharma Competition

Hookipa Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Hookipa Pharma in relation to its competition. Hookipa Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Hookipa Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Hookipa Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Hookipa Pharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Hookipa Pharma position

In addition to having Hookipa Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Latest Gainers Thematic Idea Now

Latest Gainers
Latest Gainers Theme
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Gainers theme has 179 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Gainers Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
How To Invest In Hookipa
Details
Is Hookipa Stock a good investment?
Details
What is Hookipa Pharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Hookipa Pharma Correlation with its peers.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. Market participants price Hookipa higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Hookipa Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(4.82)
Revenue Per Share
0.747
Quarterly Revenue Growth
(0.94)
Return On Assets
(0.45)
Return On Equity
(1.06)
Investors evaluate Hookipa Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Hookipa Pharma's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Hookipa Pharma's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Hookipa Pharma's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY